GentiBio
Shivali is an Associate Scientist II on the Discovery Research team at Gentibio, where she helps develop alternative strategies to restore Treg-mediated immune tolerance. Shivali received her BA in Biology and Computer Science from Columbia University in 2022. During her undergrad, she had the opportunity to work under Dr. Donna L. Farber, where she studied the development and tissue localization of T cell-driven immune responses in early life. As an advocate of accessibility and inclusion in science, Shivali also led Columbia’s Undergraduate Science Journal (CUSJ) as their Director of Outreach and continues on as a mentor for the group.
This person is not in any offices
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.